Search | Clinical Trials Finder

Conditions: Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female
Interventions: Pazopanib, Paclitaxel, Carboplatin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Fallopian Tube Cancer, Peritoneum Cancer, Epithelial Ovarian Cancer
Interventions: Pembrolizumab, Paclitaxel, Carboplatin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Head and Neck Cancer
Interventions: Intensity modulated radiation therapy (IMRT) with or without chemotherapy, cisplatin, cetuximab, or carboplatin-paclitaxel; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, lobradimil; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 207
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 152 more

Conditions: Esophageal Cancer
Interventions: Proton Beam Therapy, Photon Radiation Therapy, Chemotherapy; Radiation · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: BMS-986012, Carboplatin, Etoposide, Nivolumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Birmingham, Alabama • Hackensack, New Jersey • Durham, North Carolina + 4 more

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
Interventions: Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU), Carboplatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer
Interventions: neoadjuvant chemotherapy; Drug
Lead sponsor: Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 6
States / cities: Jacksonville, Florida • Lakeland, Florida • Miami, Florida + 2 more

Conditions: Childhood Hepatoblastoma, Recurrent Childhood Liver Cancer, Stage I Childhood Liver Cancer
Interventions: therapeutic conventional surgery, cisplatin, vincristine sulfate, fluorouracil, amifostine trihydrate, carboplatin; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Lung Cancer
Interventions: Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 70 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 18
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 14 more

Conditions: Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Interventions: Durvalumab, Paclitaxel, Carboplatin, Radiation, Surgical Resection; Device · Drug · Radiation + 1 more
Lead sponsor: Greg Durm, MD; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • New York, New York + 1 more

Conditions: ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Durvalumab, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2); Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 30
States / cities: Duarte, California • Glendale, California • Los Angeles, California + 25 more

Conditions: Non-small Cell Lung Cancer
Interventions: M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT); Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 21
States / cities: Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 35
States / cities: Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 22 more

Conditions: Non Small Cell Lung Carcinoma
Interventions: Pemetrexed, Carboplatin; Drug
Lead sponsor: Instituto Nacional de Cancer, Brazil; Government
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Atezolizumab, Tiragolumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Advanced Solid Tumours
Interventions: AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: carboplatin, 7-hydroxystaurosporine, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urothelial Carcinoma
Interventions: disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 89
States / cities: Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more

Conditions: Lymphoma
Interventions: filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Bevacizumab, Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 448
States / cities: Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more

Search by objective public record fields.

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).

A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer

Lobradimil and Carboplatin in Treating Children With Brain Tumors

Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery

Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery